ATE248592T1 - Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten - Google Patents

Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten

Info

Publication number: ATE248592T1
Authority: AT; Austria
Prior art keywords: medication; produce; treatment; certain diseases; naaladase inhibitors
Prior art date: 1998-12-31

Application number

AT99967675T

Other languages

English (en)

Inventor

Barbara S Slusher

Xi-Chun May Lu

Krystyna Wozniak

Original Assignee

Guilford Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-31

Filing date

1999-12-29

Publication date

2003-09-15

1999-12-29 Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc

2003-09-15 Application granted granted Critical

2003-09-15 Publication of ATE248592T1 publication Critical patent/ATE248592T1/de

Links

239000003112 inhibitor Substances 0.000 title abstract 2
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
210000004027 cell Anatomy 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 1
102000003958 Glutamate Carboxypeptidase II Human genes 0.000 abstract 1
108090000369 Glutamate Carboxypeptidase II Proteins 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000024245 cell differentiation Effects 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
210000002744 extracellular matrix Anatomy 0.000 abstract 1
230000036737 immune function Effects 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000003908 liver function Effects 0.000 abstract 1
230000023105 myelination Effects 0.000 abstract 1
230000035771 neuroregeneration Effects 0.000 abstract 1
230000004203 pancreatic function Effects 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
230000029663 wound healing Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Immunology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT99967675T 1998-12-31 1999-12-29 Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten ATE248592T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22429198A	1998-12-31	1998-12-31
US09/425,197 US6444657B1 (en)	1998-12-31	1999-10-22	Methods for treating certain diseases using naaladase inhibitors
PCT/US1999/031039 WO2000038785A2 (en)	1998-12-31	1999-12-29	Methods for treating certain diseases using naaladase inhibitors

Publications (1)

Publication Number	Publication Date
ATE248592T1 true ATE248592T1 (de)	2003-09-15

Family

ID=26918579

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99967675T ATE248592T1 (de)	1998-12-31	1999-12-29	Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten

Country Status (8)

Country	Link
US (2)	US6444657B1 (de)
EP (2)	EP1140048B1 (de)
JP (1)	JP2002533421A (de)
AT (1)	ATE248592T1 (de)
AU (1)	AU2392100A (de)
CA (1)	CA2354052A1 (de)
DE (1)	DE69911057D1 (de)
WO (1)	WO2000038785A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7070782B1 (en) *	1992-11-05	2006-07-04	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen
US7105159B1 (en)	1992-11-05	2006-09-12	Sloan-Kettering Institute For Cancer Research	Antibodies to prostate-specific membrane antigen
US6953668B1 (en)	1992-11-05	2005-10-11	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen
WO1996026272A1 (en)	1995-02-24	1996-08-29	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen and uses thereof
US6569432B1 (en)	1995-02-24	2003-05-27	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen and uses thereof
US20040253246A1 (en) *	1996-02-23	2004-12-16	Israeli Ron S.	Prostate-specific membrane antigen and uses thereof
US6444657B1 (en) *	1998-12-31	2002-09-03	Guilford Pharmaceuticals Inc.	Methods for treating certain diseases using naaladase inhibitors
WO2001019836A1 (en)	1999-09-14	2001-03-22	Meiji Seika Kaisha, Ltd.	Phosphonic acid derivatives having carboxypeptidase b inhibitory activity
AU2001265111A1 (en) *	2000-05-30	2001-12-11	Guilford Pharmaceuticals Inc.	Benzenedicarboxylic acid derivatives
CA2436408A1 (en) *	2001-02-07	2002-12-12	Beth Israel Deaconess Medical Center	Modified psma ligands and uses related thereto
US7605177B2 (en) *	2001-05-24	2009-10-20	Neuren Pharmaceuticals Limited	Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
US7714020B2 (en) *	2001-05-24	2010-05-11	Neuren Pharmaceuticals Limited	Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) *	2001-05-24	2007-01-04	Neuren Pharmaceuticals Limited	Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
EP1401808B1 (de)	2001-05-24	2009-07-08	Neuren Pharmaceuticals Limited	Gpe-analoga und peptidomimetika
WO2003034903A2 (en) *	2001-10-23	2003-05-01	Psma Development Company, L.L.C.	Psma antibodies and protein multimers
US20050215472A1 (en)	2001-10-23	2005-09-29	Psma Development Company, Llc	PSMA formulations and uses thereof
US7148250B2 (en) *	2001-12-28	2006-12-12	Guilford Pharmaceuticals Inc.	Indoles as NAALADase inhibitors
DE602004021476D1 (de) *	2003-03-03	2009-07-23	Eisai Corp North America	THIOLACTONE ALS NAALADase INHIBITOREN
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
EP2672971A4 (de) *	2011-02-11	2014-12-31	Pharmalundensis Ab	Metabotrope glutamatrezeptor-gruppe-i-antagonisten zur behandlung abnormaler gewebeverbindungen
WO2022219008A1 (en) *	2021-04-14	2022-10-20	University College Cork - National University Of Ireland, Cork	Treatment of cerebrovascular events and neurological disorders

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5156840A (en)	1982-03-09	1992-10-20	Cytogen Corporation	Amine-containing porphyrin derivatives
US4867973A (en)	1984-08-31	1989-09-19	Cytogen Corporation	Antibody-therapeutic agent conjugates
US4671958A (en)	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
US4950738A (en)	1984-09-13	1990-08-21	Cytogen Corporation	Amine derivatives of anthracycline antibiotics
US5162512A (en)	1982-03-09	1992-11-10	Cytogen Corporation	Amine derivatives of anthracycline antibodies
US5140104A (en)	1982-03-09	1992-08-18	Cytogen Corporation	Amine derivatives of folic acid analogs
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
US4857637A (en)	1986-05-07	1989-08-15	Genentech, Inc.	Methods and compositions for immunologically modulating growth hormone receptor activity
US5093525A (en)	1986-07-10	1992-03-03	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5190976A (en)	1986-07-10	1993-03-02	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon	N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4906779A (en)	1986-07-10	1990-03-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
CA1305177C (en)	1987-06-30	1992-07-14	Yasufumi Ohfune	Carboxycyclopropylglycine and process for producing the same
US4918064A (en)	1987-10-21	1990-04-17	G. D. Searle & Co.	Phenyl glycines for use in reducing neurotoxic injury
US5871472A (en)	1987-11-17	1999-02-16	Brown University Research Foundation	Planting devices for the focal release of neuroinhibitory compounds
ES2092468T3 (es)	1988-01-22	1996-12-01	Zymogenetics Inc	Metodos para producir analogos de receptores secretados.
US5567584A (en)	1988-01-22	1996-10-22	Zymogenetics, Inc.	Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US4937183A (en)	1988-02-03	1990-06-26	Cytogen Corporation	Method for the preparation of antibody-fragment conjugates
US5047227A (en)	1988-02-08	1991-09-10	Cytogen Corporation	Novel and improved antibodies for site specific attachment of compounds
US5162504A (en)	1988-06-03	1992-11-10	Cytogen Corporation	Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4966999A (en)	1988-06-07	1990-10-30	Cytogen Corporation	Radiohalogenated compounds for site specific labeling
CA2002011A1 (en)	1988-11-14	1990-05-14	Anthony F. Purchio	Normal human growth regulatory receptor for tgf-beta
US4994446A (en)	1989-01-03	1991-02-19	Ramot - University Authority For Applied Research And Industrial Development Ltd.	Drug system
US5136080A (en)	1989-12-04	1992-08-04	Burroughs Wellcome Co.	Nitrile compounds
US5336689A (en)	1990-03-02	1994-08-09	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon	Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5262568A (en)	1990-03-02	1993-11-16	State Of Oregon	Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5137877B1 (en)	1990-05-14	1996-01-30	Bristol Myers Squibb Co	Bifunctional linking compounds conjugates and methods for their production
GB9106678D0 (en)	1991-03-28	1991-05-15	Ferguson Mark W J	Wound healing
ATE196548T1 (de)	1991-05-10	2000-10-15	Genentech Inc	Auswählen von agonisten und antagonisten von liganden
JP2632754B2 (ja)	1991-05-21	1997-07-23	塩野義製薬株式会社	脳内グルタミン酸遊離抑制剤
US5229495A (en)	1991-06-18	1993-07-20	Ludwig Institute For Cancer Research	Substantially pure receptor like TGF-β 1 binding molecules and uses thereof
US5216126A (en)	1991-06-19	1993-06-01	Genentech, Inc.	Receptor polypeptides and their production and uses
US5543143A (en)	1992-03-06	1996-08-06	Corixa Corporation	Method for activating macrophages/monocytes
WO1993019177A1 (en)	1992-03-18	1993-09-30	The General Hospital Corporation	FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
US5326856A (en)	1992-04-09	1994-07-05	Cytogen Corporation	Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5668118A (en) *	1992-07-24	1997-09-16	Cavalier Pharmaceuticals	Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5489525A (en)	1992-10-08	1996-02-06	The United States Of America As Represented By The Department Of Health And Human Services	Monoclonal antibodies to prostate cells
AU669256B2 (en)	1992-10-29	1996-05-30	Celtrix Pharmaceuticals, Inc.	Uses of TGF-beta receptor fragment as a therapeutic agent
EP1757695A3 (de)	1992-11-05	2008-02-27	Sloan Kettering Institute For Cancer Research	Prostata-spezifisches Membranantigen
US5565439A (en)	1992-11-24	1996-10-15	The Procter & Gamble Company	Methods of using lysophosphatidic acid for treating hyperproliferative conditions
US5614502A (en) *	1993-01-15	1997-03-25	The General Hospital Corporation	High-pressure impulse transient drug delivery for the treatment of proliferative diseases
US5453492A (en)	1993-07-28	1995-09-26	La Jolla Cancer Research Foundation	60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5449761A (en)	1993-09-28	1995-09-12	Cytogen Corporation	Metal-binding targeted polypeptide constructs
WO1996026272A1 (en)	1995-02-24	1996-08-29	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen and uses thereof
US5500420A (en)	1993-12-20	1996-03-19	Cornell Research Foundation, Inc.	Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
US5583153A (en) *	1994-10-06	1996-12-10	Regents Of The University Of California	Use of taxol in the treatment of rheumatoid arthritis
US6011021A (en) *	1996-06-17	2000-01-04	Guilford Pharmaceuticals Inc.	Methods of cancer treatment using naaladase inhibitors
US5698402A (en)	1995-02-23	1997-12-16	Dianon Systems, Inc.	Methods for diagnosing benign prostatic hyperplasia
US5616561A (en)	1995-03-31	1997-04-01	Regents Of The University Of California	TGF-β antagonists as mitigators of radiation-induced tissue damage
US5795877A (en)	1996-12-31	1998-08-18	Guilford Pharmaceuticals Inc.	Inhibitors of NAALADase enzyme activity
US5804602A (en)	1996-06-17	1998-09-08	Guilford Pharmaceuticals Inc.	Methods of cancer treatment using naaladase inhibitors
US5672592A (en)	1996-06-17	1997-09-30	Guilford Pharmaceuticals Inc.	Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6054444A (en)	1997-04-24	2000-04-25	Guilford Pharmaceuticals Inc.	Phosphonic acid derivatives
US5824662A (en)	1996-09-27	1998-10-20	Guilford Pharmaceuticals Inc.	Treatment of global and focal ischemia using naaladase inhibitors
US5977090A (en)	1996-09-27	1999-11-02	Guilford Pharmaceuticals Inc.	Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors
US6071965A (en)	1996-06-17	2000-06-06	Guilford Pharmaceuticals Inc.	Phosphinic alkanoic acid derivatives
US5863536A (en)	1996-12-31	1999-01-26	Guilford Pharmaceuticals Inc.	Phosphoramidate derivatives
US6017903A (en)	1996-09-27	2000-01-25	Guilford Pharmaceuticals Inc.	Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6025345A (en)	1996-06-17	2000-02-15	Guilford Pharmaceuticals Inc.	Inhibitors of NAALADase enzyme activity
US6384022B1 (en)	1996-06-17	2002-05-07	Guilford Pharmaceuticals Inc.	Prodrugs of NAALAdase inhibitors
US6025344A (en)	1996-06-17	2000-02-15	Guilford Pharmaceuticals Inc.	Certain dioic acid derivatives useful as NAALADase inhibitors
US5902817A (en)	1997-04-09	1999-05-11	Guilford Pharmaceuticals Inc.	Certain sulfoxide and sulfone derivatives
US6046180A (en)	1996-06-17	2000-04-04	Guilford Pharmaceuticals Inc.	NAALADase inhibitors
WO1998013046A1 (en) *	1996-09-27	1998-04-02	Guilford Pharmaceuticals Inc.	Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
US5962521A (en)	1997-04-04	1999-10-05	Guilford Pharmaceuticals Inc.	Hydroxamic acid derivatives
US5830210A (en)	1996-10-21	1998-11-03	Plc Medical Systems, Inc.	Catheter navigation apparatus
EP0994707A4 (de)	1997-05-27	2001-11-14	Guilford Pharm Inc	Inhibitoren der naaladase-enzym-aktivität
WO1999008521A1 (en)	1997-08-14	1999-02-25	Department Of The Army, U.S. Government	Treatment or prophylaxis of retinal pathology and spinal cord injury
US5981209A (en)	1997-12-04	1999-11-09	Guilford Pharmaceuticals Inc.	Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en)	1997-12-31	2000-02-22	Guilford Pharmaceuticals Inc.	Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6121252A (en)	1998-03-30	2000-09-19	Guilford Pharmaceuticals Inc.	Phosphinic acid derivatives
US6265609B1 (en) *	1998-07-06	2001-07-24	Guilford Pharmaceuticals Inc.	Thio-substituted pentanedioic acid derivatives
MXPA01000144A (es)	1998-07-06	2002-10-17	Guilford Pharm Inc	Inhibidores de naaladasa utiles como composiciones y compuestos farmaceuticos.
US6395718B1 (en) *	1998-07-06	2002-05-28	Guilford Pharmaceuticals Inc.	Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6348329B1 (en) *	1998-11-06	2002-02-19	Fibrogen, Inc.	Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use
US6444657B1 (en) *	1998-12-31	2002-09-03	Guilford Pharmaceuticals Inc.	Methods for treating certain diseases using naaladase inhibitors
US6228888B1 (en)	1999-07-01	2001-05-08	Guilford Pharmaceuticals Inc.	Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
US6313159B1 (en)	1999-08-20	2001-11-06	Guilford Pharmaceuticals Inc.	Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors

1999
- 1999-10-22 US US09/425,197 patent/US6444657B1/en not_active Expired - Fee Related
- 1999-12-29 EP EP99967675A patent/EP1140048B1/de not_active Expired - Lifetime
- 1999-12-29 AU AU23921/00A patent/AU2392100A/en not_active Abandoned
- 1999-12-29 WO PCT/US1999/031039 patent/WO2000038785A2/en not_active Ceased
- 1999-12-29 DE DE69911057T patent/DE69911057D1/de not_active Expired - Lifetime
- 1999-12-29 JP JP2000590733A patent/JP2002533421A/ja active Pending
- 1999-12-29 CA CA002354052A patent/CA2354052A1/en not_active Abandoned
- 1999-12-29 EP EP03019536A patent/EP1371367A1/de not_active Withdrawn
- 1999-12-29 AT AT99967675T patent/ATE248592T1/de not_active IP Right Cessation
2002
- 2002-08-01 US US10/209,011 patent/US6806261B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2392100A (en)	2000-07-31
EP1140048B1 (de)	2003-09-03
US6444657B1 (en)	2002-09-03
JP2002533421A (ja)	2002-10-08
US20030017965A1 (en)	2003-01-23
EP1140048A2 (de)	2001-10-10
WO2000038785A3 (en)	2000-09-21
WO2000038785A2 (en)	2000-07-06
US6806261B2 (en)	2004-10-19
DE69911057D1 (de)	2003-10-09
EP1371367A1 (de)	2003-12-17
CA2354052A1 (en)	2000-07-06

Legal Events

Date	Code	Title	Description
2004-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69911057D1 (de)	2003-10-09	Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten
Hawkins et al.	2006	The role of laser fluence in cell viability, proliferation, and membrane integrity of wounded human skin fibroblasts following helium‐neon laser irradiation
Chandra et al.	2015	Peroxide‐based oxygen generating topical wound dressing for enhancing healing of dermal wounds
Heng	2011	Wound healing in adult skin: aiming for perfect regeneration
Carriel et al.	2013	Combination of fibrin-agarose hydrogels and adipose-derived mesenchymal stem cells for peripheral nerve regeneration
Diniz et al.	2018	Photobiomodulation of mesenchymal stem cells encapsulated in an injectable rhBMP4‐loaded hydrogel directs hard tissue bioengineering
Eweida et al.	2015	Naturally occurring extracellular matrix scaffolds for dermal regeneration: do they really need cells?
Leong et al.	2016	Mesenchymal stem cells in tendon repair and regeneration: basic understanding and translational challenges
Abedin‐Do et al.	2022	Electrical stimulation promotes the wound‐healing properties of diabetic human skin fibroblasts
Houreld et al.	2007	In vitro exposure of wounded diabetic fibroblast cells to a helium-neon laser at 5 and 16 J/cm2
Hu et al.	2006	Evaluation of Apligraf® persistence and basement membrane restoration in donor site wounds: a pilot study
DE69525151D1 (de)	2002-03-14	Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
Swope et al.	2002	Regulation of cutaneous pigmentation by titration of human melanocytes in cultured skin substitutes grafted to athymic mice
ATE270323T1 (de)	2004-07-15	Zusammensetzungen und verfahren zur stimulierung der proliferation und der differenzierung von menschlichen fetalen und erwachsenen pankreatischen zellen ex vivo
Liu et al.	2004	Autologous cultured keratinocytes on porcine gelatin microbeads effectively heal chronic venous leg ulcers
DE69203596D1 (de)	1995-08-24	Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
Chiu et al.	2023	Tissue engineering-based strategies for diabetic foot ulcer management
ATE368455T1 (de)	2007-08-15	Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
Desvigne et al.	2021	Case report: surgical closure of chronic soft tissue defects using extracellular matrix graft augmented tissue flaps
WO2004011631A3 (en)	2004-04-08	Methods and compositions for treating tissue defects using pulsed electromagnetic field stimulus
Panahi et al.	2024	Effect of Piascledine‐bacterial nanocellulose combination on experimental cutaneous wound healing in rat: Histopathological, biochemical and molecular studies
ATE352306T1 (de)	2007-02-15	Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
Wu et al.	2025	Melatonin-loaded hydrogel modulates circadian rhythms and alleviates oxidative stress and inflammation to promote wound healing
Fimiani et al.	2005	Other uses of homologous skin grafts and skin bank bioproducts
Boggio et al.	2008	Is there an easier way to autograft skin in chronic leg ulcers?‘Minced micrografts’, a new technique